ArticleClinical neurophysiology practice2026
Long-term neuromuscular alterations during botulinum toxin treatment for chronic migraine.
Article in Clinical neurophysiology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Re-assessing the clinical significance of long-term neuromuscular alterations following Onabotulinumtoxin-A (BoNTA) in chronic migraine: Letter to the editor on behalf of the GRASP study group.Clinical neurophysiology practice · 2026Article
- Response to: 'Re-assessing the clinical significance of long-term neuromuscular alterations following onabotulinumtoxinA in chronic migraine'.Clinical neurophysiology practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate early and long-term neuromuscular and clinical effects of botulinum toxin type A (BoNTA) in women with chronic migraine undergoing sustained treatment. Methods: Forty female patients were stratified by cumulative BoNTA exposure (treatment-naïve, ∼1 year, 2-5 years, >5 years). Clinical outcomes included migraine frequency, pain burden, and quality of life. Neurophysiological assessments during one treatment cycle comprised motor nerve conduction studies, quantitative EMG, jitter analysis, and blink reflex. Serum neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) were also measured. Results: BoNTA significantly reduced migraine days ( Conclusions: BoNTA is associated with persistent neuromuscular alterations, with early effects in facial muscles and cumulative changes in the trapezius. Significance: These findings support the occurrence of treatment-dependent neuromuscular side effects and highlight the need for monitoring during long-term therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.